<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00405964</url>
  </required_header>
  <id_info>
    <org_study_id>P04684</org_study_id>
    <nct_id>NCT00405964</nct_id>
  </id_info>
  <brief_title>Study for the Treatment of Persistent Allergic Rhinitis With Desloratadine (Study P04684)</brief_title>
  <official_title>Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter/Multinational, Efficacy and Safety Study of Desloratadine 5 mg in the Treatment of Subjects With Allergic Rhinitis Who Meet the Criteria for Persistent Allergic Rhinitis (PER)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the effectiveness of desloratadine in treating subjects with
      allergic rhinitis who meet the criteria for persistent allergic rhinitis (PER)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Participant's AM/PM PRIOR Total 5 Symptom Score (T5SS) Over Days 1 to 29 of Treatment</measure>
    <time_frame>Baseline and Days 1-29</time_frame>
    <description>AM/PM PRIOR (the participant's status over previous 12 hours) T5SS from the participant's daily diary averaged over treatment Days 1 to 29. AM/PM is the average of separate morning (AM) and evening (PM) evaluations. Scores were defined for T5SS as 0: no symptoms to 15: all severe symptoms. A two-way analysis of variance (ANOVA) model with treatment and site effects was used to examine the treatment difference.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Total Rhinoconjunctivitis Quality of Life Questionnaire-Standarized Version (RQLQ-S) After 29 Days of Treatment</measure>
    <time_frame>Baseline and Day 29</time_frame>
    <description>The RQLQ-S was only completed for participants above 18 years of age. The RQLQ-S was not available for participants 12 to 17 years of age. This questionnaire asked questions pertaining to daily activities, sleep, non-nose eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotions. The scale went from 0 (not troubled) to 6 (extremely troubled). A two-way analysis of variance (ANOVA) model with treatment and site effects was used to examine the treatment difference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Participant's AM/PM PRIOR T5SS Over Days 1 to 85 of Treatment</measure>
    <time_frame>Baseline and Days 1-85</time_frame>
    <description>AM/PM PRIOR (the participant's status over previous 12 hours) T5SS from the participant's daily diary averaged over treatment Days 1 to 85. AM/PM is the average of separate AM and PM evaluations. Scores were defined for T5SS as 0: no symptoms to 15: all severe symptoms. A two-way analysis of variance (ANOVA) model with treatment and site effects was used to examine the treatment difference.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">716</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>5-mg Desloratadine tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-mg Desloratadine</intervention_name>
    <description>5-mg Desloratadine tablet, once daily for 12 weeks</description>
    <arm_group_label>5-mg Desloratadine tablet</arm_group_label>
    <other_name>SCH 34117, Aerius</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablet</intervention_name>
    <description>Placebo tablet, once daily for 12 weeks</description>
    <arm_group_label>Placebo tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For this study, the diagnosis of persistent allergic rhinitis (PER) is not based
             solely on the current episode of allergic rhinitis (AR). Subjects must have at least a
             2 year history of AR consistent with PER (defined as symptoms of allergic rhinitis
             present more than four days per week and for more than four consecutive weeks per
             year); the current episode can count as the second year.

          -  Subjects must be 12 years of age and older, of either sex and of any race.

          -  At the Run-in Visit, subjects must be sufficiently symptomatic, with a T5SS 12-hour
             AM-PRIOR (Subject's Status Over Previous 12 Hours) symptoms severity score of at least
             8.

          -  In order for a subject to qualify at the Baseline Visit, the sum of the daily averages
             of the diary recordings of the 12-hour AM PRIOR + PM-PRIOR T5SS collected during Days
             -4 to -1 and the AM PRIOR T5SS on the morning of the Baseline Visit (Day 1) must be
             &gt;=40.

          -  Subjects must have a positive skin-prick test at screening to one or more allergens in
             the Global Allergy and Asthma European Network (GA2LEN) (or the usually used local)
             panel of seasonal and perennial allergens. Subjects must demonstrate an
             antigen-induced skin prick wheal at least 3 mm in diameter greater than diluent
             control. The positive tests must include the allergen(s) prevalent while this study is
             active.

          -  Subjects must be free of any clinically significant disease, other than PER, which
             would interfere with the study evaluations.

          -  Subjects, or parents or legal guardians, must give written informed consent. Subjects
             must be able to adhere to dose, visit schedules and meet study requirements.

          -  In females of childbearing potential, the urine pregnancy test (human chorionic
             gonadotropin [hCG]) must be negative at the Screening Visit.

          -  Nonsterile or premenopausal female subjects must be using a medically accepted method
             of birth control, that is, oral contraceptive, hormonal implant, medically prescribed
             intra-uterine device (IUD), or depot injectable during the entire study. A female
             subject who is not currently sexually active must agree and consent to use one of the
             above-mentioned methods, if she becomes sexually active while participating in the
             study. A female subject who is not of childbearing potential must have a medical
             record of being surgically sterile (for example, hysterectomy, and tubal ligation), or
             be at least 1 year postmenopausal.

        Exclusion Criteria:

          -  Subjects with a history of anaphylaxis and/or severe local reactions(s) to skin
             testing with allergens.

          -  Subjects with intolerable symptoms that would make participating in the study
             unbearable.

          -  Subjects who have had an upper respiratory tract or sinus infection that required
             antibiotic therapy, and have not had at least a 14-day washout prior to the run-in
             period, or who have had a viral upper respiratory infection within 7 days prior to
             screening.

          -  Subjects with asthma who require chronic use of inhaled or systemic corticosteroids.

          -  Subjects with a current history of frequent, clinically significant sinusitis or
             chronic purulent postnasal drip.

          -  Subjects on immunotherapy (desensitization therapy) unless on a regular maintenance
             schedule prior to Visit 1 and staying on this schedule for the remainder of the study.

          -  Subjects who, in the opinion of the investigator, are dependent on nasal, oral or
             ocular decongestants, nasal topical antihistamines or nasal steroids.

          -  Subjects who have used any drug or device in an investigational protocol in the 30
             days prior to Visit 1.

          -  Female subjects who are pregnant or nursing.

          -  Subjects with a history of hypersensitivity to the study drug or to their excipients
             or known to not tolerate any antihistamine.

          -  Subject is a member of the Investigational Study Staff (currently involved with this
             study) or a member of the staff's family.

          -  Subjects with current evidence of clinically significant hematopoietic,
             cardiovascular, hepatic, renal, neurologic, psychiatric, autoimmune disease, or other
             disease that preclude the subject's participation in the study.

          -  Subjects whose ability to provide informed consent is compromised.

          -  Subjects with a history of noncompliance with medications or treatment protocols.

          -  Subjects with rhinitis medicamentosa.

          -  Subjects who have, in the opinion of the investigator or designee, clinically
             significant nasal structural abnormalities, including large nasal polyps or marked
             septum deviation, that significantly interferes with nasal air flow.

          -  Subjects who have not observed mediation washout times prior to visit 2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Turkey</country>
  </removed_countries>
  <results_reference>
    <citation>Bousquet J, Bachert C, Canonica GW, Mullol J, Van Cauwenberge P, Jensen CB, Fokkens WJ, Ring J, Keith P, Gopalan G, Lorber R, Zuberbier T; ACCEPT-2 Study Group. Efficacy of desloratadine in persistent allergic rhinitis - a GA²LEN study. Int Arch Allergy Immunol. 2010;153(4):395-402. doi: 10.1159/000316351. Epub 2010 Jun 18.</citation>
    <PMID>20559006</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2006</study_first_submitted>
  <study_first_submitted_qc>November 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2006</study_first_posted>
  <results_first_submitted>March 25, 2009</results_first_submitted>
  <results_first_submitted_qc>October 22, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 19, 2010</results_first_posted>
  <last_update_submitted>March 15, 2017</last_update_submitted>
  <last_update_submitted_qc>March 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Desloratadine</mesh_term>
    <mesh_term>Loratadine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>5-mg Desloratadine Tablet</title>
          <description>Desloratadine 5 mg orally daily. Dosing was to be in the morning (AM) within 1 hour of awakening.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Tablet</title>
          <description>Matching placebo, orally daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="360"/>
                <participants group_id="P2" count="356"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="301"/>
                <participants group_id="P2" count="261"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="95"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Treatment Failure</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>5-mg Desloratadine Tablet</title>
          <description>Desloratadine 5 mg orally daily. Dosing was to be in the morning (AM) within 1 hour of awakening.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Tablet</title>
          <description>Matching placebo, orally daily.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="360"/>
            <count group_id="B2" value="356"/>
            <count group_id="B3" value="716"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="348"/>
                    <measurement group_id="B2" value="341"/>
                    <measurement group_id="B3" value="689"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.0" spread="12.1"/>
                    <measurement group_id="B2" value="33.9" spread="12.3"/>
                    <measurement group_id="B3" value="33.9" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="208"/>
                    <measurement group_id="B2" value="198"/>
                    <measurement group_id="B3" value="406"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="152"/>
                    <measurement group_id="B2" value="158"/>
                    <measurement group_id="B3" value="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Participant's AM/PM PRIOR Total 5 Symptom Score (T5SS) Over Days 1 to 29 of Treatment</title>
        <description>AM/PM PRIOR (the participant’s status over previous 12 hours) T5SS from the participant's daily diary averaged over treatment Days 1 to 29. AM/PM is the average of separate morning (AM) and evening (PM) evaluations. Scores were defined for T5SS as 0: no symptoms to 15: all severe symptoms. A two-way analysis of variance (ANOVA) model with treatment and site effects was used to examine the treatment difference.</description>
        <time_frame>Baseline and Days 1-29</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>5-mg Desloratadine Tablet</title>
            <description>Desloratadine 5 mg orally daily. Dosing was to be in the morning (AM) within 1 hour of awakening.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablet</title>
            <description>Matching placebo, orally daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Participant's AM/PM PRIOR Total 5 Symptom Score (T5SS) Over Days 1 to 29 of Treatment</title>
          <description>AM/PM PRIOR (the participant’s status over previous 12 hours) T5SS from the participant's daily diary averaged over treatment Days 1 to 29. AM/PM is the average of separate morning (AM) and evening (PM) evaluations. Scores were defined for T5SS as 0: no symptoms to 15: all severe symptoms. A two-way analysis of variance (ANOVA) model with treatment and site effects was used to examine the treatment difference.</description>
          <population>All randomized participants</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="355"/>
                <count group_id="O2" value="351"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.63" spread="0.13"/>
                    <measurement group_id="O2" value="9.55" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 1-29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.76" spread="0.22"/>
                    <measurement group_id="O2" value="-2.87" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>Determined for site. P-value of &lt;.001 for treatment as well.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Total Rhinoconjunctivitis Quality of Life Questionnaire-Standarized Version (RQLQ-S) After 29 Days of Treatment</title>
        <description>The RQLQ-S was only completed for participants above 18 years of age. The RQLQ-S was not available for participants 12 to 17 years of age. This questionnaire asked questions pertaining to daily activities, sleep, non-nose eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotions. The scale went from 0 (not troubled) to 6 (extremely troubled). A two-way analysis of variance (ANOVA) model with treatment and site effects was used to examine the treatment difference.</description>
        <time_frame>Baseline and Day 29</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>5-mg Desloratadine Tablet</title>
            <description>Desloratadine 5 mg orally daily. Dosing was to be in the morning (AM) within 1 hour of awakening.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablet</title>
            <description>Matching placebo, orally daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Total Rhinoconjunctivitis Quality of Life Questionnaire-Standarized Version (RQLQ-S) After 29 Days of Treatment</title>
          <description>The RQLQ-S was only completed for participants above 18 years of age. The RQLQ-S was not available for participants 12 to 17 years of age. This questionnaire asked questions pertaining to daily activities, sleep, non-nose eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotions. The scale went from 0 (not troubled) to 6 (extremely troubled). A two-way analysis of variance (ANOVA) model with treatment and site effects was used to examine the treatment difference.</description>
          <population>All randomized participants</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="313"/>
                <count group_id="O2" value="289"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.30" spread="0.08"/>
                    <measurement group_id="O2" value="3.15" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.35" spread="0.10"/>
                    <measurement group_id="O2" value="-0.95" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.035</p_value>
            <p_value_desc>Determined for site. Treatment p-value &lt;.001</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Participant's AM/PM PRIOR T5SS Over Days 1 to 85 of Treatment</title>
        <description>AM/PM PRIOR (the participant’s status over previous 12 hours) T5SS from the participant's daily diary averaged over treatment Days 1 to 85. AM/PM is the average of separate AM and PM evaluations. Scores were defined for T5SS as 0: no symptoms to 15: all severe symptoms. A two-way analysis of variance (ANOVA) model with treatment and site effects was used to examine the treatment difference.</description>
        <time_frame>Baseline and Days 1-85</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>5-mg Desloratadine Tablet</title>
            <description>Desloratadine 5 mg orally daily. Dosing was to be in the morning (AM) within 1 hour of awakening.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablet</title>
            <description>Matching placebo, orally daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Participant's AM/PM PRIOR T5SS Over Days 1 to 85 of Treatment</title>
          <description>AM/PM PRIOR (the participant’s status over previous 12 hours) T5SS from the participant's daily diary averaged over treatment Days 1 to 85. AM/PM is the average of separate AM and PM evaluations. Scores were defined for T5SS as 0: no symptoms to 15: all severe symptoms. A two-way analysis of variance (ANOVA) model with treatment and site effects was used to examine the treatment difference.</description>
          <population>All randomized participants</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="355"/>
                <count group_id="O2" value="351"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.63" spread="0.13"/>
                    <measurement group_id="O2" value="9.55" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 1-85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.50" spread="0.23"/>
                    <measurement group_id="O2" value="-3.61" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>Same p-value for treatment and site.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>5-mg Desloratadine Tablet</title>
          <description>Desloratadine 5 mg orally daily. Dosing was to be in the morning (AM) within 1 hour of awakening.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Tablet</title>
          <description>Matching placebo, orally daily.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="356"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulum Intestinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Lower Limb Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="356"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="356"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="44" subjects_affected="38" subjects_at_risk="360"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="356"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="45" subjects_affected="25" subjects_at_risk="360"/>
                <counts group_id="E2" events="63" subjects_affected="37" subjects_at_risk="356"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

